The conversations on this week’s podcast are with CEO of Merz Therapeutics, Stefan König, about a variety of neurodegenerative conditions and a botulinum neurotoxin, and with CEO of Kainova Therapeutics, Sean MacDonald, about – among other things – G-protein coupled receptors, or GPCRs.

Times:

03:21 Merz Therapeutics

30:34 Kainova Therapeutics

Kainova Therapeutics

Kainova Therapeutics is a clinical-stage biopharmaceutical company headquartered in Montreal, Canada. The company develops drug candidates targeting GPCRs, with programmes focused on immuno-oncology and inflammatory diseases.

The company’s pipeline includes antibody and small-molecule programmes directed at GPCR targe ...